← Eichor
Study identifier: NCT05922124 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Cefiderocol and Ampicillin-sulbactam vs. Colistin +/- Meropenem for Carbapenem Resistant A. Baumannii

Condition: Carbapenem Resistant Bacterial Infection · Acinetobacter Bacteremia · Acinetobacter Pneumonia  ·  Sponsor: Rambam Health Care Campus

PhasePhase 4
Planned participants734
Who can joinAll sexes, 16 Years to no upper limit
Healthy volunteersNo

About this study

Patients with bloodstream infections, hospital acquired pneumonia or ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii (CRAB) treated with cefiderocol combined with ampicillin sulbactam will be compared to patients treated treated with colistin alone or colistin combined with meropenem.

This description comes directly from the study's public registry record.

Talk to the study team

Mical Paul  ·  0502062140  ·  paulm@technion.ac.il

Marco Falcone  ·  marco.falcone@unipi.it

Always discuss trial participation with your own doctor first.

Locations (3)

Rambam Health Care CampusHaifa, IsraelRecruiting
Sheba Tel HaShomer Medical CampusRamat Gan, IsraelRecruiting
Shamir Medical Center (Assaf Harofeh)Tel Aviv, IsraelRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05922124